Serotonin dysregulation in Fragile X Syndrome: Implications for treatment

Intractable and Rare Diseases Research

Volumn 3, Issue 4, 2014, Pages 110-117

  Hanson, Alicia C ^a   Hagerman, Randi J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

fragile X mental retardation protein; Fragile X Syndrome; selective serotonin reuptake inhibitors; sertraline

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; PAROXETINE; SEROTONIN; SERTRALINE;

AUTISM; DRUG EFFICACY; FRAGILE X SYNDROME; GENE EXPRESSION; HUMAN; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; REVIEW; SEROTONIN BRAIN LEVEL; UPREGULATION;

EID: 85010120460     PISSN: 21863644     EISSN: 2186361x     Source Type: Journal    
DOI: 10.5582/irdr.2014.01027     Document Type: Article

References (71)

1. Abbeduto L, Hagerman RJ. Language and communication in fragile X syndrome. Ment Retard Dev Disabil Res. 1997; 3:313-322.
2. Sudhalter V, Belser RC. Conversational characteristics of children with fragile X syndrome: Tangential language. Am J Ment Retard. 2001 Sep;106:389-400.
3. Budimirovic DB, Kaufmann WE. What can we learn about autism from studying fragile X syndrome? Dev Neuro sci. 2011; 33:379-394.
4. Williams TA, Langdon RM, Porter MA. Hyper-reactivity in fragile X syndrome females: Generalised or specific to socially-salient stimuli? A skin conductance study. Int J Psychophysiol. 2013; 88:26-34.
5. Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: Prevalence and characterization. J Neurodev Disord. 2011; 3:57-67.
6. Munir F, Cornish KM, Wilding J. A neuropsychological profile of attention deficits in young males with fragile X syndrome. Neuropsychologia. 2000; 38:1261-1270.
7. Miller LJ, McIntosh DN, McGrath J, Shyu V, Lampe M, Taylor AK, Tassone F, Neitzel K, Stackhouse T, Hagerman RJ. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: A preliminary report. Am J Med Genet. 1999; 83:268-279.
8. Hagerman RJ, Hagerman PJ. “The Physical and Behavioral Phenotype.” Johns Hopkins University Press. 2002, Baltimore.
9. Bardoni B, Mandel JL, Fisch GS. FMR1 gene and fragile X syndrome. Am J Med Genet. 2000; 97:153-163.
10. Tejada MI, Glover G, Martinez F, Guitart M, de Diego-Otero Y, Fernandez-Carvajal I, Ramos FJ, Hernandez-Chico C, Pintado E, Rosell J, Calvo MT, Ayuso C, Ramos-Arroyo MA, Maortua H, Mila M. Molecular testing for Fragile X: Analysis of 5062 tests from 1105 Fragile X Families. Performed in 12 clinical laboratories in Spain. Bio Med Res Int. 2014; 2014:195793.
11. Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: A twenty-year perspective. Annu Rev Pathol. 2012; 7:219-245.
12. Hagerman RJ, Des-Portes V, Gasparini F, Jacquemont S, Gomez-Mancilla B. Translating molecular advances in fragile X syndrome into therapy: A review. J Clin Psychiatry. 2014; 75: 294-307.
13. Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: Causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012; 122:4314-4322.
14. Zang T, Maksimova MA, Cowan CW, Bassel-Duby R, Olson EN, Huber KM. Postsynaptic FMRP bidirectionally regulates excitatory synapses as a function of developmental age and MEF2 activity. Mol Cell Neuro sci. 2013; 56:39-49.
15. Gholizadeh S, Arsenault J, Xuan IC, Pacey LK, Hampson DR. Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice. Neuropsychopharmacology. 2014: 39:3100-3111
16. Van der Molen MJ, Van der Molen MW. Reduced alpha and exaggerated theta power during the resting-state EEG in fragile X syndrome. Biol Psychol. 2013; 92:216-219.
17. Lozano R, Hare EB, Hagerman RJ. Modulation of the GABAergic pathway for the treatment of fragile X syndrome. Neuropsychiatr Dis Treat. 2014; 10:1769-1799.
18. Hare EB, Hagerman RJ, Lozano R. Targeted treatments in fragile X syndrome. Expert Opin Orphan Drugs. 2014; 2:531-543.
19. Pop AS, Gomez-Mancilla B, Neri G, Willemsen R, Gasparini F. Fragile X syndrome: A preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development. Psychopharmacology. 2014;231:1217-1226
20. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004; 27:370-377.
21. Costa L, Spatuzza M, D'Antoni S, Bonaccorso CM, Trovato C, Musumeci, SA, Leopoldo M, Lacivita E, Catania MV, Ciranna L. Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptormediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of fragile X syndrome. Biol Psychiat. 2012; 72:924-933.
22. Zhang J, Hou L, Klann E, Nelson DL. Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models. J Neurophysiol. 2009; 101:2572-2580.
23. Lim CS, Hoang ET, Viar KE, Stornetta RL, Scott MM, Zhu JJ. Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model. Genes Dev. 2014; 28:273-289.
24. Hessl D, Tassone F, Cordeiro L, Koldewyn K, McCormick C, Green C, Wegelin J, Yuhas J, Hagerman R.J. Brief report: Aggression and stereotypic behavior in males with fragile X syndrome. moderating secondary genes in a “single gene” disorder. J Autism Dev Disord. 2008; 38:184-189.
25. McDuffie A, Kover ST, Hagerman RJ, Abbeduto L. Investigating word learning in fragile X syndrome: A fast-mapping study. J Autism Dev Disord. 2013, 43:1676-1691.
26. Iossifov I, Ronemus M, Levy D, et al. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012; 74:285-299.
27. Harris SW, Hessl D, Goodlin-Jones B, Ferranti J, Bacalman S, Barbato I, Tassone F, Hagerman PJ, Herman H, Hagerman R.J. Autism profiles of males with fragile X syndrome. Am J Ment Retard. 2008; 113:427-438.
28. Boccuto L, Chen CF, Pittman AR, Skinner CD, McCartney HJ, Jones K, Bochner BR, Stevenson RE, Schwartz CE. Decreased tryptophan metabolism in patients with autism spectrum disorders. Mol Autism. 2013; 4:16.
29. McDougle C, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiat. 1996; 53:993-1000.
30. Kronk R, Bishop EE, Raspa M, Bickel JO, Mandel DA, Bailey DB Jr. Prevalence, nature, and correlates of sleep problems among children with fragile X syndrome based on a large scale parent survey. Sleep. 2010; 33:679-687.
31. Wirojanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, Hagerman RJ, Goodlin-Jones BL. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009; 5:145-150.
32. Chugani DC, Muzik O, Chakraborty P, Mangner T, Chugani H.T. Human brain serotonin synthesis capacity measured in vivo with α-[C-11] methyl-L-tryptophan. Synpase. 1998; 28:33-43.
33. Chandana SR, Behen ME, Juhasz C, Muzik O, Rothermel RD, Mangner TJ, Chakraborty PK, Chugani HT, Chugani DC. Significance of abnormalities in developmental trajectory and asymmetry of cortical serotonin synthesis in autism. Int J Dev Neuro sci. 2005; 23:171-182.
34. Bianchi P, Ciani E, Guidi S, Trazzi S, Felice D, Grossi G, Fernandez M, Giuliani A, Calza L, Bartesaghi R. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci 2010; 30:8769-8779.
35. Taler M, Miron O, Gil-Ad I, Weizman A. Neuroprotective and procognitive effects of sertraline: In vitro and in vivo studies. Neuroscience Lett. 2013; 550:93-97.
36. Altar CA, Boylan CB, Fritsche M, Jackson C, Hyman C, Lindsay RM. The neurotrophins NT-4/5 and BDNF augment serotonin, dopamine, and GABAergic systems during behaviorally effective infusions to the substantia nigra. Exp Neurol. 1994; 130:31-40.
37. Bartkowska K, Paquin A, Gauthier AS, Kaplan DR, Miller FD. Trk signaling regulates neural precursor cell proliferation and differentiation during cortical development. Development. 2007; 134:4369-4380.
38. Fukumitsu H, Ohtsuka M, Murai R, Nakamura H, Itoh K, Furukawa S. Brain-derived neurotrophic factor participates in determination of neuronal laminar fate in the developing mouse cerebral cortex. J Neurosci. 2006; 26:13218-13230.
39. Jansson LC, Louhivuori L, Wigren HK, Nordström T, Louhivuori V, Castrén ML, Åkerman KE. Brain-derived neurotrophic factor increases the motility of a particular Nmethyl-D-aspartate/GABA-responsive subset of neural progenitor cells. Neuroscience. 2012; 8:223-234.
40. Alder J, Kramer BC, Hoskin C, Thakker-Varia S. Brain-derived neurotrophic factor produced by human umbilical tissue-derived cells is required for its effect on hippocampal dendritic differentiation. Dev Neurobiol. 2012; 72:755-765.
41. Pan F, Aldridge GM, Greenough WT, Gan WB. Dendritic spine instability and insensitivity to modulation by sensory experience in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A. 2010; 107:17768-17773.
42. Zoghbi HY, Bear MF. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb Perspect Biol 2012; 4:pii:a009886.
43. Castrén M, Tervonen T, Kärkkäinen V, Heinonen S, Castrén E, Larsson K, Bakker CE, Oostra BA, Åkerman K. Altered differentiation of neural stem cells in fragile X syndrome. Proc Natl Acad Sci U S A. 2005; 102:17834-17839.
44. Lauterborn JC, Rex CS, Kramár E, Chen LY, Pandyarajan V, Lynch G, Gall CM. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci. 2007; 27:10685-10694.
45. Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, Oostra B, Bagni C. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell. 2003; 112:317-327.
46. Bassell GJ, Warren ST. Fragile X syndrome: Loss of local mRNA regulation alters synaptic development and function. Neuron. 2008; 60:201-214.
47. Castrén ML, Castrén E. BDNF in fragile X syndrome. Neuropharmacology. 2014; 76:729-736.
48. Grossman AW, Aldridge GM, Weiler IJ, Greenough WT. Local protein synthesis and spine morphogenesis: Fragile X syndrome and beyond. J Neurosci. 2006; 26:7151-7155.
49. Taurines R, Segura M, Schecklmann M, et al. Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder. J Neural Transm. 2014; 121:1117-1128.
50. Castrén M, Lampinen KE, Miettinen R, Koponen E, Sipola I, Bakker CE, Oostra BA, Castrén E. BDNF regulates the expression of fragile X mental retardation protein mRNA in the hippocampus. Neurobiol Dis. 2002; 11:221-229.
51. Luo Y, Shan G, Guo W, Smrt RD, Johnson EB, Li X, Pfeiffer RL, Szulwach KE, Duan R, Barkho BZ, Li W, Liu C, Jin P, Zhao X. Fragile X mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet. 2010; 6:e1000898.
52. Uutela M, Lindholm J, Rantamäki T, Umemori J, Hunter K, Võikar V, Castrén ML. Distinctive behavioral and cellular responses to fluoxetine in the mouse model for Fragile X syndrome. Front Cell Neurosci. 2014; 28:150.
53. Saffary R, Xie Z. FMRP regulates the transition from radial glial cells to intermediate progenitor cells during neocortical development. J Neurosci. 2011; 31:1427-1439.
54. Louhivuori V, Vicario A, Uutela M, Rantamäki T, Louhivuori LM, Castrén E, Tongiorgi E, Akerman KE, Castrén ML. BDNF and TrkB in neuronal differentiation of Fmr1-knockout mouse. Neurobiol Dis 2011; 41:469-480.
55. Uutela M, Lindholm J, Louhivuori V, Wei H, Louhivuori LM, Pertovaara A, Akerman K, Castrén E, Castrén ML. Reduction of BDNF expression in Fmr1 knockout mice worsens cognitive deficits but improves hyperactivity and sensorimotor deficits. Genes Brain Behav. 2012; 11:513-523.
56. Tervonen TA, Louhivuori V, Sun X, Hokkanen ME, Kratochwil CF, Zebryk P, Castrén E, Castrén ML. Aberrant differentiation of glutamatergic cells in neocortex of mouse model for fragile X syndrome. Neurobiol Dis. 2009; 33:250-259.
57. Guo W, Allan AM, Zong R, Zhang L, Johnson EB, Schaller EG, Murthy AC, Goggin SL, Eisch AJ, Oostra BA, Nelson DL, Jin P, Zhao X. Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning. Nat Med. 2011; 17:559-565.
58. Berry-Kravis E. Mechanism-Based Treatments in Neurodevelopmental Disorders: Fragile X Syndrome. Pediatr Neurol. 2014; 50:297-302.
59. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, Picker J, Gane L, Tranfaglia M. Advances in the treatment of fragile X syndrome. Pediatrics. 2009; 123:378-390.
60. Busquets-Garcia A, Gomis-González M, Guegan T, Agustín-Pavón C, Pastor A, Mato S, Pérez-Samartín A, Matute C, de la Torre R, Dierssen M, Maldonado R, Ozaita A. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat Med. 2013; 19:603-607.
61. Erickson CA, Wink LK, Ray B, Early MC, Stiegelmeyer E, Mathieu-Frasier L, Patrick V, Lahiri DK, McDougle CJ. Impact of acamprosate on behavior and brain-derived neurotrophic factor: An open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013; 228:75-84.
62. Osterweil EK, Chuang SC, Chubykin AA, Sidorov M, Bianchi R, Wong RK, Bear MF. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron. 2013; 77:243-250.
63. de Vries BB, Robinson H, Stolte-Dijkstra I, Tjon Pian Gi CV, Dijkstra PF, van Doorn J, Halley DJ, Oostra BA, Turner G, Niermeijer MF. General overgrowth in the fragile X syndrome: Variability in the phenotypic expression of the FMR1 gene mutation. J Med Genet. 1995; 32:764-769.
64. Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome. present and future. Ment Retard Dev Disabil Rev. 2004; 10:42-48.
65. Indah Winarni T, Chonchaiya W, Adams E, Au J, Mu Y, Rivera SM, Nguyen DV, Hagerman R.J. Sertraline may improve language developmental trajectory in young children with fragile X syndrome: A retrospective chart review. Autism Res Treat. 2012; 2012:104371.
66. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders. I. Basic pharmacology. J Psychopharmacol. 1998; 12(3 Suppl B):5-20.
67. Kitaichi Y, Inoue T, Nakagawa S, Boku S, Kakuta A, Izumi T, Koyama T. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol. 2010; 647:90-96.
68. Money KM, Stanwood GD. Developmental origins of brain disorders: Roles for dopamine. Front Cell Neurosci. 2013; 7:260.
69. Villalba RM, Lee H, Smith Y. Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys. Exp Neurol. 2009; 215:220-227.
70. Wang H, Wu LJ, Kim SS, Lee FJ, Gong B, Toyoda H, Ren M, Shang YZ, Xu H, Liu F, Zhao MG, Zhuo M. FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron. 2008; 59:634-647.
71. Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discov Today. 2009; 14(13-14):690-697.